Currently out of the existing stock ratings of Steve Beuchaw, 32 are a SELL (23.88%), 47 are a HOLD (35.07%), 55 are a BUY (41.04%).

Steve Beuchaw

Work Performance Price Targets & Ratings Chart

Analyst Steve Beuchaw, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 72.19% that have a potential upside of 20.62% achieved within 332 days. Previously, Steve Beuchaw worked at WOLFE.

Steve Beuchaw’s has documented 259 price targets and ratings displayed on 25 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on QGEN, Qiagen NV at 06-Jan-2025.

Wall Street Analyst Steve Beuchaw

Analyst best performing recommendations are on ALGN (ALIGN TECHNOLOGY).
The best stock recommendation documented was for ALGN (ALIGN TECHNOLOGY) at 10/9/2018. The price target of $320 was fulfilled within 1 day with a profit of $20.97 (6.15%) receiving and performance score of 61.5.

Average potential price target upside

of $47.64 (18.73%) on ALGN (ALIGN TECHNOLOGY).
of $42.02 (19.54%) on ILMN (ILLUMINA).
of $37.18 (13.59%) on TMO (THERMO FISHER SCIENTIFIC).

ALGN Align Technology BRKR Bruker ILMN Illumina ISRG Intuitive Surgical MDT Medtronic PLC QGEN Qiagen NV SDC SmileDirectClub XRAY Dentsply Sirona A Agilent Technologies TMO Thermo Fisher Scientific DHR Danaher HSIC Henry Schein MYGN Myriad Genetics OCDX Ortho Clinical Diagnostics Holdings plc PDCO Patterson Companies MTD Mettler-Toledo International PKI PerkinElmer VAR Varian Medical Systems NTRA Natera BIO Bio-Rad Laboratories ABT Abbott Laboratories BSX Boston Scientific Corp EW Edwards Lifesciences Corp SYK Stryker ZBH Zimmer Biomet Holdings

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Glen Santangelo (BARCLAYS)